Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses his company’s orphan oncology pipeline.

The Company’s growth strategy is primarily driven by the development of its orphan oncology candidates which meet an established and unaddressed therapeutic need for a relatively limited population of patients, and products with very high sales potential – benefiting from more favorable price and reimbursement policies.

Onxeo’s orphan oncology products are:

– Livatag (doxorubicin Transdrug): in Phase III in the treatment of primary liver cancer
– Beleodaq (belinostat): registered in the U.S. in relapsed or refractory peripheral T-cell lymphoma (PTCL)
– AsiDNA: The first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I trial in metastatic melanoma.
– Validive (clonidine Lauriad): finalized positive results of Phase II in the treatment and prevention of radio/chemotherapy induced severe oral mucositis in patients suffering from head and neck cancer. The company is seeking for a partner to further co-develop Validive.

In the medium to long term, the Company could market directly these high value-added products with a strong profitability profile in order to benefit from the full profit margin generated.

Furthermore, Onxeo has successfully developed and registered two non-strategic drugs in Europe and the United States, demonstrating its teams’ expertise and know-how.

These products are based on Onxeo’s innovative proprietary technology Lauriad that makes it possible to improve the efficacy and tolerance profile of an active ingredient for the chosen indication: Loramyc/Oravig , indicated for the treatment of oropharyngeal candidiasis, and Sitavig/Labiriad, indicated for the treatment of recurrent herpes labialis. With a strong market potential, these products are dedicated to be marketed by international partners, mainly via licensing agreements, contributing towards the funding of development projects.